FY2022 · ended Dec 31, 2022 · Revenue $0, -100.0% YoY · Filed Mar 22, 2024
Decoy Therapeutics Inc. (DCOY) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$5.4 million.
Revenue
$0
-100.0% vs prior year
Net income (TTM)
$-14.45M
-183.1% vs year-ago TTM
Operating cash flow (TTM)
$-8.32M
-100.9% vs year-ago TTM
Free cash flow
$-5.40M
+47.0% vs prior year
EPS (TTM)
$-40.72
-253.3% vs year-ago TTM
Dividend per share
None
Shares outstanding
531,968
-69.5% vs prior year
Net cash
—
Operating margin
-696.3%
FY 2021
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- DCOY (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Houston, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1615219
- Former names
- Salarius Pharmaceuticals, Inc. (until Jan 9, 2026); Flex Pharma, Inc. (until Jul 22, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $1.8M |
| Operating income | -$12.6M | -$5.7M | -$12.9M | -$31.8M | -$12.8M |
| Net income | -$12.5M | -$5.6M | -$12.5M | -$31.6M | -$12.8M |
| Diluted EPS | -$129.10 | -$69.54 | -$30.74 | -$14.88 | -$7.72 |
| Operating cash flow | -$4.8M | -$4.5M | -$12.8M | -$17.6M | -$10.2M |
| Free cash flow | -$5.4M | — | — | — | -$10.2M |
| Total assets | $11.1M | $3.0M | $6.6M | $14.7M | $40.8M |
| Total liabilities | $5.2M | $1.5M | $1.3M | $4.3M | $2.1M |
| Stockholders' equity | $5.9M | $1.5M | $5.3M | $10.4M | $38.7M |
| Cash and investments | $10.7M | $2.4M | $5.9M | $12.1M | $29.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Sep 23, 2026 | Sep 22, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Sep 15, 2026 | Sep 14, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jul 15, 2026 | Jul 14, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Jun 29, 2026 | Jun 26, 2026 |
| 8-K |
Current report
Other events
|
May 19, 2026 | May 19, 2026 |
All 743 Decoy Therapeutics Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.